Experimental and therapeutic medicine
March 2023
Octavian Vasiliu
Treatment-resistant depression (TRD) is a challenge for psychiatrists, even after more than seven decades since the first antidepressants were used in clinical practice. Non-monoaminergic-based drugs with antidepressant properties have been developed, but to date, only esketamine and brexanolone have been approved for TRD and postpartum depression, respectively. A narrative review on the...
PubMed Central
March 1, 2023
INTRODUCTION: Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88). Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI), increases remission and response rates in patients with TRD...
Journal of Affective Disorders
March 1, 2023
Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira et al.
25 citations
Background: ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). Methods: We searched MEDLINE, Web of Science, Embase,...
Journal of Affective Disorders
February 28, 2023
Ming Jiang, Qianqian Li, Mingjie Mao et al.
Background: Patients with missed miscarriages are usually accompanied by varying degrees of depression, which is closely related to the patient's prognosis. We investigated whether Esketamine could alleviate postoperative depression symptoms in patients with missed miscarriages who underwent painless curettage. Methods: This study was a randomized, parallel-controlled, double-blind,...
February 28, 2023
Ketamine therapies can offer rapid relief of depression and an antisuicidal effect, making them of particular interest for adolescents with treatment-resistant depression. In 1 randomized, double-blind study of adolescents with severe major depression, ketamine had a strong effect size for reducing depressive symptoms 24 hours after infusion. Currently, there is minimal investigation and few...
Frontiers in Cellular Neuroscience
February 15, 2023
Cui-Hong Zhou, Xinxin Zhao, Xinxu Ma et al.
Introduction: Compelling evidence indicates that a single sub-anesthetic dose of (S)-ketamine elicits rapid and robust antidepressant effects. However, the underlying mechanisms behind the antidepressant effects of (S)-ketamine remain unclear. Methods: Here, using a chronic variable stress (CVS) model in mice, we analyzed changes inthe lipid compositions of the hippocampus and prefrontal cortex...
European Archives of Psychiatry and Clinical Neuroscience
February 14, 2023
Kenji Hashimoto
40 citations
Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) in these patients, these drugs have not been found to improve cognitive impairment. The N-methyl-D-aspartate receptor antagonist...
Frontiers in Neuroscience
February 2, 2023
Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al.
Background Dysfunction of the amygdala is the core pathogenesis of major depressive disorder (MDD). However, it remains unclear whether ketamine treatment could modulate characteristics of amygdala-related networks. We aimed to explore the relationship between changes in the resting-state functional connectivity (RSFC) of the amygdala and the treatment of ketamine in MDD patients and to...
The Brown University Psychopharmacology Update
February 1, 2023
Results of a systematic review and meta‐analysis comprising six clinical trials suggest that electroconvulsive therapy (ECT) is more efficacious than ketamine in reducing the severity of depressive symptoms in patients with a major depressive episode. No significant between‐group differences in the prevalence of adverse events were observed. Results of the meta‐analysis were published online...
Neuropharmacology
February 1, 2023
Taro Kato
Conventional antidepressant medications act on monoaminergic systems and have important limitations, including a therapeutic delay of weeks to months and low rates of efficacy. Recently, clinical findings have indicated that ketamine, a dissociative anesthetic that blocks N-methyl-d-aspartate receptor channel activity, causes rapid and long-lasting antidepressant effects. Although the exact...